​

RxSight (RXST) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RXST Stock Forecast

RxSight (RXST) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $75.25, with a high of $110.00 and a low of $52.00. This represents a 421.48% increase from the last price of $14.43.

$10 $30 $50 $70 $90 $110 High: $110 Avg: $75.25 Low: $52 Last Closed Price: $14.43

RXST Stock Rating

RxSight stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (62.50%), 2 Hold (25.00%), 1 Sell (12.50%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 2 5 Strong Sell Sell Hold Buy Strong Buy

RXST Price Target Upside V Benchmarks

TypeNameUpside
StockRxSight421.48%
SectorHealthcare Stocks 35.25%
IndustryMedical Device Stocks21.20%

Price Target Trends

1M3M12M
# Anlaysts--14
Avg Price Target--$69.64
Last Closing Price$14.43$14.43$14.43
Upside/Downside--382.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25352--10
Mar, 25352--10
Feb, 25352--10
Jan, 25352--10
Dec, 24372--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 29, 2024Curry BakerGuggenheim$52.00$52.00-260.36%
Oct 29, 2024Anthony CrowdellMizuho Securities$67.00$52.0028.85%364.31%
Oct 29, 2024Adam SeidenBarclays$110.00$52.00111.54%662.30%
Oct 29, 2024Young LiJefferies$72.00$50.2543.28%398.96%
Sep 23, 2024Ryan ZimmermanBTIG$59.00$52.9811.36%308.87%
Sep 13, 2024David SaxonNeedham$66.00$54.5421.01%357.38%
Aug 06, 2024Thomas StephanStifel Nicolaus$65.00$40.7859.39%350.45%
Aug 06, 2024David SaxonNeedham$54.00$47.1514.53%274.22%
May 07, 2024Steven LichtmanOppenheimer$72.00$62.8414.58%398.96%
May 07, 2024David SaxonNeedham$75.00$62.8419.35%419.75%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 15, 2025Piper SandlerNeutralinitialise
Oct 29, 2024BarclaysOverweightinitialise
Oct 29, 2024Wells FargoBuyBuyhold
Oct 29, 2024JefferiesBuyinitialise
Sep 23, 2024BTIGBuyBuyhold
Sep 13, 2024Wells FargoBuyBuyhold
Sep 13, 2024NeedhamBuyBuyhold
Aug 06, 2024NeedhamBuyBuyhold
May 07, 2024Stifel NicolausBuyBuyhold
May 07, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.78$-2.41$-1.41$-0.71----
Avg Forecast$-2.66$-2.61$-1.53$-0.72$-0.45$-0.05$-0.08$-0.14
High Forecast$-2.51$-2.50$-1.48$5.06$-0.13$0.03$-0.07$-0.14
Low Forecast$-2.79$-2.78$-1.56$-5.06$-0.90$-0.12$-0.08$-0.14
Surprise %-33.08%-7.66%-7.84%-1.39%----

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$22.59M$49.01M$89.08M$139.93M----
Avg Forecast$22.04M$48.76M$88.44M$140.03M$188.50M$231.79M$284.80M$300.70M
High Forecast$22.84M$51.18M$89.27M$140.10M$189.45M$232.46M$295.90M$303.50M
Low Forecast$21.04M$47.21M$86.59M$139.97M$187.66M$231.11M$273.70M$294.39M
Surprise %2.53%0.50%0.72%-0.07%----

Net Income Forecast

$-200M $-120M $-40M $40M $120M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-48.69M$-66.76M$-48.61M$-27.45M----
Avg Forecast$-91.76M$-89.86M$-52.40M$-30.69M$-17.24M$-1.03M$-2.56M$-4.82M
High Forecast$-86.38M$-86.15M$-51.02M$174.36M$-4.59M$973.35K$-2.51M$-4.69M
Low Forecast$-96.13M$-95.64M$-53.78M$-174.36M$-30.96M$-4.14M$-2.62M$-4.88M
Surprise %-46.94%-25.71%-7.24%-10.55%----

RXST Forecast FAQ

Is RxSight stock a buy?

RxSight stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that RxSight is a favorable investment for most analysts.

What is RxSight's price target?

RxSight's price target, set by 8 Wall Street analysts, averages $75.25 over the next 12 months. The price target range spans from $52 at the low end to $110 at the high end, suggesting a potential 421.48% change from the previous closing price of $14.43.

How does RxSight stock forecast compare to its benchmarks?

RxSight's stock forecast shows a 421.48% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the medical device stocks industry (21.20%).

What is the breakdown of analyst ratings for RxSight over the past three months?

  • April 2025: 30.00% Strong Buy, 50.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 30.00% Strong Buy, 50.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 30.00% Strong Buy, 50.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is RxSight’s EPS forecast?

RxSight's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.45, marking a -36.62% decrease from the reported $-0.71 in 2024. Estimates for the following years are $-0.05 in 2026, $-0.08 in 2027, and $-0.14 in 2028.

What is RxSight’s revenue forecast?

RxSight's average annual revenue forecast for its fiscal year ending in December 2025 is $188.5M, reflecting a 34.72% increase from the reported $139.93M in 2024. The forecast for 2026 is $231.79M, followed by $284.8M for 2027, and $300.7M for 2028.

What is RxSight’s net income forecast?

RxSight's net income forecast for the fiscal year ending in December 2025 stands at $-17.241M, representing a -37.20% decrease from the reported $-27.455M in 2024. Projections indicate $-1.029M in 2026, $-2.564M in 2027, and $-4.824M in 2028.